<p>根據 Benzinga 的報道，Bank of America 的股票研究分析師在週一發佈的報告中，將 Vertex Pharmaceuticals（納斯達克代碼：VRTX）的目標價格從 555.00 美元上調至 567.00 美元。該券商目前對這家制藥公司的股票給予 “買入” 評級。Bank of America 的目標價格意味着該股票相較於之前的收盤價有 15.08% 的潛在上漲空間。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p>其他一些股票研究分析師最近也對 VRTX 發佈了報告。Cantor Fitzgerald 在 2 月 11 日的研究報告中重申了對 Vertex Pharmaceuticals 的 “增持” 評級，並給出了 480.00 美元的目標價格。巴克萊將 Vertex Pharmaceuticals 的目標價格從 435.00 美元上調至 467.00 美元，並在 2 月 11 日的報告中給予該股票 “持平” 評級。Piper Sandler 在 1 月 27 日的研究報告中將 Vertex Pharmaceuticals 的目標價格從 535.00 美元下調至 533.00 美元，並對該公司給予 “增持” 評級。Truist Financial 在 2 月 11 日的報告中將 Vertex Pharmaceuticals 的目標價格從 460.00 美元上調至 520.00 美元，並給予該公司 “買入” 評級。最後，富國銀行在 1 月 30 日的報告中將 Vertex Pharmaceuticals 的評級從 “增持” 下調至 “持平”，並設定了 460.00 美元的目標價格。十位投資分析師對該股票給予了持有評級，十六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 508.65 美元。</p>
<p><strong>查看我們最新的 VRTX 股票報告</strong></p>
<h2>Vertex Pharmaceuticals 股票表現</h2>
<ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
<p>VRTX 的股票在週一以 492.69 美元開盤。該公司的 50 日移動平均線為 476.45 美元，200 日移動平均線為 463.64 美元。公司的市值為 1265.2 億美元，市盈率為-223.95，市盈增長比率為 2.11，貝塔值為 0.41。公司的債務股本比率為 0.01，流動比率為 2.69，速動比率為 2.35。Vertex Pharmaceuticals 的年低為 377.85 美元，年高為 519.88 美元。</p>
<p>Vertex Pharmaceuticals（納斯達克代碼：VRTX）最近在 2 月 10 日發佈了季度財報。該製藥公司報告的每股收益為 3.54 美元，低於分析師一致預期的 3.99 美元，差距為 0.45 美元。Vertex Pharmaceuticals 的股本回報率為-2.02%，淨利潤率為-4.86%。整體來看，股票分析師預測 Vertex Pharmaceuticals 在本年度的每股收益將達到 15.63 美元。</p>
<h2>內部買賣情況</h2>
<ul>
<li>2 只基因編輯股票在 2025 年有強勁反彈的潛力</li>
</ul>
<p>在其他 Vertex Pharmaceuticals 的新聞中，執行副總裁 Ourania Tatsis 在 2 月 18 日的交易中出售了 244 股公司的股票。該股票以 455.06 美元的平均價格出售，總價值為 111,034.64 美元。交易後，該執行副總裁現在直接持有 67,695 股公司的股票，價值約為 30,805,286.70 美元。此次交易使其持股減少了 0.36%。該出售在向證券交易委員會的備案中披露，可以通過此鏈接訪問。此外，執行副總裁 David Altshuler 在 3 月 10 日的交易中出售了 3,231 股公司的股票。該股票以 500.00 美元的平均價格出售，總交易額為 1,615,500.00 美元。出售後，該執行副總裁現在直接持有 26,512 股公司的股票，價值約為 13,256,000 美元。此次交易使其持股減少了 10.86%。該出售的披露信息可以在此找到。內部人士在上個季度出售了 4,315 股公司股票，價值為 2,121,012 美元。內部人士持有公司股票的比例為 0.20%。</p>
<h2>對 Vertex Pharmaceuticals 的對沖基金看法</h2>
<p>一些機構投資者和對沖基金最近對 VRTX 的持倉進行了調整。公共部門養老金投資委員會在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 14.2%。公共部門養老金投資委員會現在持有 11,244 股該製藥公司的股票，價值為 5,229,000 美元，在此期間又增持了 1,400 股。Captrust Financial Advisors 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 2.2%。Captrust Financial Advisors 現在持有 14,409 股該製藥公司的股票，價值為 6,701,000 美元，在此期間又增持了 307 股。Kestra Investment Management LLC 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 28.7%。Kestra Investment Management LLC 現在持有 2,315 股該製藥公司的股票，價值為 1,077,000 美元，在上個季度又增持了 516 股。Benjamin Edwards Inc.在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 4,913.5%。Benjamin Edwards Inc.現在持有 6,668 股該製藥公司的股票，價值為 3,101,000 美元，在上個季度又增持了 6,535 股。最後，Beck Capital Management LLC 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Beck Capital Management LLC 現在持有 2,004 股該製藥公司的股票，價值為 932,000 美元，在上個季度又增持了 38 股。機構投資者持有公司股票的比例為 90.96%。</p>
<h2>Vertex Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變、年齡在 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為年齡在 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於 ivacaftor 治療。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Vertex Pharmaceuticals 更具吸引力</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Lululemon 回調至經典的買入機會</li>
<li>初學者如何閲讀股票圖表</li>
<li>Cintas 發佈盈利超預期，預示未來增長</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>分析師表示這四隻低市盈率消費週期股值得買入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

福泰制藥

<p>美國銀行已將 Vertex Pharmaceuticals（納斯達克代碼：VRTX）的目標股價從 555.00 美元上調至 567.00 美元，維持 “買入” 評級。這個新目標暗示該股票相較於前一交易日收盤價有 15.08% 的潛在上漲空間。其他分析師也調整了他們的評級，普遍評級為 “適度買入”，平均目標股價為 508.65 美元。Vertex 的股票開盤價為 492.69 美元，市值為 1265.2 億美元。該公司報告上個季度每股收益為 3.54 美元，低於預期 0.45 美元</p>

<p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price objective boosted by equities research analysts at Bank of America from $555.00 to $567.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the pharmaceutical company's stock. Bank of America's price objective would indicate a potential upside of 15.08% from the stock's previous close.</p>
<div class="lb-trans"><p>根據 Benzinga 的報道，Bank of America 的股票研究分析師在週一發佈的報告中，將 Vertex Pharmaceuticals（納斯達克代碼：VRTX）的目標價格從 555.00 美元上調至 567.00 美元。該券商目前對這家制藥公司的股票給予 “買入” 評級。Bank of America 的目標價格意味着該股票相較於之前的收盤價有 15.08% 的潛在上漲空間。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p>A number of other equities research analysts have also recently issued reports on VRTX. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an &#34;equal weight&#34; rating in a report on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, January 27th. Truist Financial raised their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 11th. Finally, Wells Fargo &amp; Company cut Vertex Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $460.00 price target for the company. in a report on Thursday, January 30th. Ten investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $508.65.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對 VRTX 發佈了報告。Cantor Fitzgerald 在 2 月 11 日的研究報告中重申了對 Vertex Pharmaceuticals 的 “增持” 評級，並給出了 480.00 美元的目標價格。巴克萊將 Vertex Pharmaceuticals 的目標價格從 435.00 美元上調至 467.00 美元，並在 2 月 11 日的報告中給予該股票 “持平” 評級。Piper Sandler 在 1 月 27 日的研究報告中將 Vertex Pharmaceuticals 的目標價格從 535.00 美元下調至 533.00 美元，並對該公司給予 “增持” 評級。Truist Financial 在 2 月 11 日的報告中將 Vertex Pharmaceuticals 的目標價格從 460.00 美元上調至 520.00 美元，並給予該公司 “買入” 評級。最後，富國銀行在 1 月 30 日的報告中將 Vertex Pharmaceuticals 的評級從 “增持” 下調至 “持平”，並設定了 460.00 美元的目標價格。十位投資分析師對該股票給予了持有評級，十六位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價格為 508.65 美元。</p>
</div><p><strong>View Our Latest Stock Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 VRTX 股票報告</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表現</h2>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛藥：大型製藥公司的下一個重大成功？</li>
</ul>
</div><p>Shares of VRTX opened at $492.69 on Monday. The firm has a 50-day moving average of $476.45 and a 200-day moving average of $463.64. The company has a market cap of $126.52 billion, a PE ratio of -223.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.</p>
<div class="lb-trans"><p>VRTX 的股票在週一以 492.69 美元開盤。該公司的 50 日移動平均線為 476.45 美元，200 日移動平均線為 463.64 美元。公司的市值為 1265.2 億美元，市盈率為-223.95，市盈增長比率為 2.11，貝塔值為 0.41。公司的債務股本比率為 0.01，流動比率為 2.69，速動比率為 2.35。Vertex Pharmaceuticals 的年低為 377.85 美元，年高為 519.88 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（納斯達克代碼：VRTX）最近在 2 月 10 日發佈了季度財報。該製藥公司報告的每股收益為 3.54 美元，低於分析師一致預期的 3.99 美元，差距為 0.45 美元。Vertex Pharmaceuticals 的股本回報率為-2.02%，淨利潤率為-4.86%。整體來看，股票分析師預測 Vertex Pharmaceuticals 在本年度的每股收益將達到 15.63 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票在 2025 年有強勁反彈的潛力</li>
</ul>
</div><p>In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 over the last quarter. Insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新聞中，執行副總裁 Ourania Tatsis 在 2 月 18 日的交易中出售了 244 股公司的股票。該股票以 455.06 美元的平均價格出售，總價值為 111,034.64 美元。交易後，該執行副總裁現在直接持有 67,695 股公司的股票，價值約為 30,805,286.70 美元。此次交易使其持股減少了 0.36%。該出售在向證券交易委員會的備案中披露，可以通過此鏈接訪問。此外，執行副總裁 David Altshuler 在 3 月 10 日的交易中出售了 3,231 股公司的股票。該股票以 500.00 美元的平均價格出售，總交易額為 1,615,500.00 美元。出售後，該執行副總裁現在直接持有 26,512 股公司的股票，價值約為 13,256,000 美元。此次交易使其持股減少了 10.86%。該出售的披露信息可以在此找到。內部人士在上個季度出售了 4,315 股公司股票，價值為 2,121,012 美元。內部人士持有公司股票的比例為 0.20%。</p>
</div><h2>Hedge Funds Weigh In On Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Vertex Pharmaceuticals 的對沖基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in VRTX. Public Sector Pension Investment Board grew its stake in Vertex Pharmaceuticals by 14.2% in the third quarter. Public Sector Pension Investment Board now owns 11,244 shares of the pharmaceutical company's stock valued at $5,229,000 after acquiring an additional 1,400 shares during the period. Captrust Financial Advisors grew its position in Vertex Pharmaceuticals by 2.2% in the 3rd quarter. Captrust Financial Advisors now owns 14,409 shares of the pharmaceutical company's stock valued at $6,701,000 after purchasing an additional 307 shares during the period. Kestra Investment Management LLC increased its stake in Vertex Pharmaceuticals by 28.7% during the 3rd quarter. Kestra Investment Management LLC now owns 2,315 shares of the pharmaceutical company's stock valued at $1,077,000 after purchasing an additional 516 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Vertex Pharmaceuticals by 4,913.5% during the third quarter. Benjamin Edwards Inc. now owns 6,668 shares of the pharmaceutical company's stock worth $3,101,000 after buying an additional 6,535 shares during the last quarter. Finally, Beck Capital Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.9% in the third quarter. Beck Capital Management LLC now owns 2,004 shares of the pharmaceutical company's stock valued at $932,000 after buying an additional 38 shares in the last quarter. Institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近對 VRTX 的持倉進行了調整。公共部門養老金投資委員會在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 14.2%。公共部門養老金投資委員會現在持有 11,244 股該製藥公司的股票，價值為 5,229,000 美元，在此期間又增持了 1,400 股。Captrust Financial Advisors 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 2.2%。Captrust Financial Advisors 現在持有 14,409 股該製藥公司的股票，價值為 6,701,000 美元，在此期間又增持了 307 股。Kestra Investment Management LLC 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 28.7%。Kestra Investment Management LLC 現在持有 2,315 股該製藥公司的股票，價值為 1,077,000 美元，在上個季度又增持了 516 股。Benjamin Edwards Inc.在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 4,913.5%。Benjamin Edwards Inc.現在持有 6,668 股該製藥公司的股票，價值為 3,101,000 美元，在上個季度又增持了 6,535 股。最後，Beck Capital Management LLC 在第三季度將其在 Vertex Pharmaceuticals 的持股增加了 1.9%。Beck Capital Management LLC 現在持有 2,004 股該製藥公司的股票，價值為 932,000 美元，在上個季度又增持了 38 股。機構投資者持有公司股票的比例為 90.96%。</p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化（CF）的療法。它為至少有一個 F508del 突變、年齡在 2 歲或以上的 CF 患者銷售 TRIKAFTA/KAFTRIO；為年齡在 6 歲或以上的 CF 患者銷售 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者銷售 ORKAMBI；以及為 1 歲或以上的 CF 患者銷售 KALYDECO，適用於 ivacaftor 治療。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Lululemon Pulls Back Into Classic Dip-Buying Opportunity</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Cintas Delivers Earnings Beat, Signals More Growth Ahead</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Vertex Pharmaceuticals 更具吸引力</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>Lululemon 回調至經典的買入機會</li>
<li>初學者如何閲讀股票圖表</li>
<li>Cintas 發佈盈利超預期，預示未來增長</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>分析師表示這四隻低市盈率消費週期股值得買入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

美國銀行將福泰製藥（NASDAQ:VRTX）的目標價上調至 567.00 美元